bacterial enzymes. Our structures suggest soraphen insure time per frame was drastically reduced in order to hibits the BC domain by an unexpected mechanism. It collect a complete three-wavelength MAD data set in may bind in the dimer interface, thereby disrupting the this time. This restricted the diffraction limit of the data oligomerization of this domain, which is crucial for its set to 2.9 Å resolution. catalytic activity. The structural observation is supThe positions of the Se atoms and the phases of the ported by our native gel electrophoresis experiments. reflections were determined from the MAD data with the We have developed a fluorescence-based binding assay, program Solve (Terwilliger and Berendzen, 1999) , and which allowed us to characterize the effects of singlethe noncrystallographic symmetry (NCS) relationships site mutations in the soraphen binding site on inhibiamong the three molecules of the BC domain in the tor sensitivity. crystallographic asymmetric unit were determined based on the resulting atomic model. The phase information was transferred to a data set to 1.8 Å resolution collected Results and Discussion on a native crystal (Table 1) , and NCS averaging using the program DM (CCP4, 1994) was used to improve and Structure Determination extend the phases. The electron density map at 1.8 Å The crystal structure of the BC domain of yeast ACC resolution was of excellent quality, and most of the in complex with soraphen A was determined at 2.9 Å atomic model was built automatically (Terwilliger and resolution by the seleno-methionyl multiwavelength Berendzen, 1999). anomalous diffraction (MAD) technique (Hendrickson, Interestingly, several attempts at solving the structure 1991). These seleno-methionyl crystals actually difusing the single-wavelength anomalous diffraction fracted to much higher resolutions at the beginning of (SAD) method were not successful, as it was not possithe experiment, but they suffered serious radiation damble to locate the Se atoms based on the SAD data. After age during the data collection. Good quality diffraction lasted only about 5 hr in the X-ray beam, and the expothe structure was solved by the MAD method, the Se while the B-domain is a lid on the cylinder ( Figure 2D ).
The structural observation is consistent with kinetic data showing that soraphen A is generally noncompetitive with respect to the substrates of ACC (Behrbohm, 1996). There are extensive interactions between soraphen A placement were not successful either, which is likely due to the large structural differences between the two and the BC domain ( Figure 3A ), explaining the nanomolar binding affinity of this natural product. In addition, enzymes (see below).
The three BC domain molecules in the asymmetric most of the residues that are involved in binding soraphen A are highly conserved among the BC domains of unit do not form dimeric or trimeric association in the crystal, consistent with our light-scattering studies eukaryotic ACCs ( Figure 1C site. The methoxy group on C12 is located in a small pocket on the surface of the enzyme ( Figure 3C ). Intercontains a nine-stranded antiparallel ␤ sheet (␤12-␤20), with helices (␣M-␣U) on both sides ( Figure 2C) . estingly, our structure suggests that small, hydrophobic , and it can be reduced (producing soraphen F) with site. We selected those residues in this region that show differences to their equivalents in the E. coli BC subunit, only a moderate loss of activity (Hofle et al., 1995) . Interestingly, removing the hydroxyl group on C5 only proand introduced these changes to yeast BC domain as single-site mutations. The mutants were expressed and duces a 5-fold loss of activity (Kiffe et al., 1997), suggesting that the hydrogen bond to Ser77 may not be purified following the same protocol as the wild-type enzyme. They migrated as monomers on a gel-filtration crucial for the activity of soraphen A ( Figure 3B) . column (data not shown), suggesting that the mutations have not disturbed the overall structure of the BC doMolecular Basis for the Specificity of Soraphen main. These mutants generally have drastically reduced To understand the molecular basis for the specificity of affinity for soraphen (Table 2) , confirming the structural soraphen A for eukaryotic BC domains, we compared information and suggesting another molecular mechathe structures of the yeast BC domain and bacterial nism for the specificity of soraphen for the BC domains BC subunit (Thoden et al., 2000; Waldrop et al., 1994) .
of eukaryotic ACCs. The K73R mutant has a 500-fold Despite sharing 35% amino acid sequence identity, loss in affinity for soraphen, such that the K d is now in there are significant differences between the two structhe micromolar range (Table 2) . At the same time, the tures ( Figures 2C and 4A) . Only 364 of the 447 C␣ atoms conservative F510I mutation has only a minor impact of the E. coli BC structure can be superimposed to within on the affinity for soraphen (Table 2) What is the molecular mechanism for the potent inhibitory activity of soraphen A? One possibility is that sora-3 Å toward the soraphen molecule, and strand ␤18 is absent in the E. coli BC structure ( Figure 4B ). As a consephen A allosterically interferes with either substrate binding or catalysis in the active site. However, based on quence, the molecular surface of bacterial BC subunit is incompatible with soraphen A binding ( Figure 4C) , our structures and the current biochemical information, this is unlikely to be the case. and there is serious steric clash between soraphen and residues in strand ␤19 of the bacterial BC structure. In To assess whether there are conformational changes in the BC domain upon soraphen binding, we have deteraddition to these differences in main chain conformations, changes in amino acid side chains in this binding mined the crystal structure of the free enzyme of yeast BC domain at 2.5 Å resolution (Table 1 ). The overall site are also detrimental for soraphen binding to the bacterial BC subunit (see below). Overall, structural and structure of the free enzyme is the same as that of the soraphen complex (see Supplemental Figure S1A at amino acid sequence differences between the bacterial and eukaryotic BC determine the specificity of soraphen http://www.molecule.org/cgi/content/full/16/6/881/ DC1/), and the rms distance for all the equivalent C␣ for eukaryotic ACCs. atoms of the two structures is 0.6 Å . In addition, there are only small changes in the soraphen binding site A Fluorescence-Based Binding Assay (Supplemental Figure S1B) and the active site. This sugWe next developed a fluorescence-based binding assay gests that soraphen binding does not induce an overall using the structural information. Our structures show conformational change in the BC domain, making an that Trp487 is mostly exposed to the solvent in the free allosteric effect on the active site by soraphen unlikely. enzyme but is buried by soraphen A in the complex The structural observation is also supported by our ( Figure 3A Figures 1C and 5A) , and it is likely that the to their inhibition.
subunits (
Wild-type 2.0 Ϯ 0.9 3.9 Ϯ 0.7
However, the exact molecular mechanism for the di- Figure 5B ). Based on our structural information, domains of ACCs is rather limited, between 25% and it is highly likely that this sharp band corresponds to 40% sequence identity. In addition, our studies show the BC:soraphen complex, in a monomeric state, whereas that soraphen does not bind in the active site, and the the smeared bands with reduced mobility correspond sequence conservation for its binding site is even lower. to dimeric or oligomeric states of the enzyme ( Figure  In fact, residues that interact with soraphen in the ACCs 5B). As a control, the mobility of the K73R mutant of the are not conserved in the other biotin enzymes. This is BC domain, which has drastically reduced affinity for strongly supported by published results showing that soraphen (Table 2) 
